Cytokinetics +32% after Q4 earnings beat estimates, revenue soars

|By:, SA News Editor

Cytokinetics (CYTK +31.9%) skyrockets higher after Q4 results beat estimates on the top and bottom line, with revenue growth of more than 1,000%.

Q4 EPS of $0.22 beat expectations of an $0.08 loss, while revenues rose 1,012% Y/Y to $24.3M vs. $19.1M analyst consensus estimate.

CYTK says it expects to announce results from BENEFIT-ALS in the next few months, and is preparing for potential next steps in the development program for tirasemtiv and the planned advancement of omecamtiv mecarbil into the final expansion phase of COSMIC-HF.